Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870929 | 0.80 | ALDH1A1 (0.54) | ALDH1A1ALOX5HSD11B1MGLLATM | |
| SCHEMBL6937627 | 0.80 | FAAH (0.38) | ALDH1A1MGLLL3MBTL1BTKMEN1 | |
| SCHEMBL31195523 | 0.74 | CRBN (0.69) | ALDH1A1ALOX5HSD11B1MGLLATM | |
| SCHEMBL29782640 | 0.74 | BTK (0.38) | ALDH1A1HSD11B1BTKDDB1CRBN | |
| SCHEMBL17699529 | 0.74 | BTK (0.38) | ALDH1A1HSD11B1BTKDDB1CRBN | |
| SCHEMBL1634757 | 0.73 | ALDH1A1 (0.62) | ALDH1A1ALOX5HSD11B1MGLLL3MBTL1 | |
| SCHEMBL12460062 | 0.73 | ALOX5 (0.49) | ALDH1A1ALOX5HSD11B1MGLLATM | |
| SCHEMBL29930250 | 0.73 | ALDH1A1 (0.62) | ALDH1A1ALOX5HSD11B1MGLLL3MBTL1 | |
| SCHEMBL21805910 | 0.72 | ALDH1A1 (0.56) | ALDH1A1ALOX5HSD11B1MGLLL3MBTL1 | |
| SCHEMBL13591667 | 0.72 | CYP11B1 (0.44) | ALDH1A1ALOX5HSD11B1MGLLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209656-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | ALDH1A1 3724/4885ALOX5 2850/4885HSD11B1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.